SRPTSarepta Therapeutics, Inc.

$19.47

Is it safe?

Can SRPT take a bad year?

The deepest fall in SRPT's price history on file is −93%; it is −20% below its high today.

$185M

Net debt · as at Q1 2026 · debt less the cash on hand

Altman Z-score
-1.10

Altman Z-score · distress zone, below 1.8

Interest cover
none

Interest cover · no operating profit to pay the interest bill from

Annualised volatility
87%

Annualised volatility · three times the market's own swing

Details
Total debtQ1 2026
$838M
Cash and short-term investments
$653M
Net debt
$185M
EBITDA, trailing twelve months
−$24M
Operating profit, trailing twelve months
−$41M
Debt / equity
0.56×
Annualised volatilitytwo years of daily moves
87%
Worst drawdown on file
−93%
Below its 52-week high
−20%

Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.